WHO

Dear Delegates,

My name is Artemis Polychronopoulou Komini and I am the Main Chair of the World Health Organization (WHO) Committee, a role which I will be sharing with my Co-Chair, Alexandros Panagiotis Ritsos. I have taken this role of serving as Main Chair at the 1st Logos MUN conference with great pleasure and I hope you all will find your role as a delegate with the same excitement.

I would first and foremost like to welcome you all to the WHO. Our goal is to lead global efforts to expand global health coverage, as well as coordinate the world's response to health emergencies. It should be emphasized that this study guide should not be the only point from which you derive knowledge but should serve as a mere starting point and reference guide to your research. While all information you can acquire is useful, it is vital for your experience as a delegate to form your own ideas, because it is of utmost importance that you understand the topic thoroughly enough for your views to be truly yours, so there is as little misunderstanding among us as possible.

I am open to any inquiries and you can contact me per email. Please do not hesitate to ask whatever may be troubling you and holding you back from reaching your full potential regarding this conference.

I wish you all a fun and fruitful debate,

Best regards,

Artemis Polychronopoulou Komini
Chair *of* WHO

Email: artwilliamspro@gmail.com

Dear Delegates,

My name is Alexandros Panagiotis Ritsos, I am an IB1 student, and I will be serving as a Co-Chair of the WHO at the innovative and truly unique Logos MUN conference. This will be my first ever experience as a chair, and words cannot describe how thankful I am for this opportunity. I cannot wait to see every one of you and listen to your unique perspectives and ideas.

I am hoping that, during our collaboration at this year's WHO, we will get to create an environment where experienced and less experienced delegates can work creatively to learn about the functions of MUN and the fascinating aspects of diplomacy. At the same time, of course, we will spend two days in an enjoyable setting. In the same way that my forerunners did for me, I will do everything in my power to ensure that everyone feels included and leaves the conference feeling inspired and motivated.

This guide will introduce you to the two topics on this year's WHO agenda. If you have any questions, feel free to contact me. I am looking forward to a productive debate with you all!

Yours truly,

Alexandros Ritsos
Co-Chair *of* WHO

Email: ar9653@geitonas.edu.gr

Forum: *World Health Organization (WHO)*

Issue: *Fostering a solution for the ongoing opioid pandemic*

Student Officers: *Artemis Polychronopoulou Komini (Chair);*

Ritsos Alexandros Panagiotis (Co-Chair)

Introduction

Opioids are a kind of medication that is mainly used to relieve pain. One good example is morphine, which is usually prescribed after an operation for pain management. However, due to the addictive nature of this medication, patients must be rigorously monitored to ensure the medications are being correctly used.

Despite this, there have been countless examples of pharmaceutical companies, such as Purdue Pharma, who saw an opportunity to ramp up their profits. These companies sent out marketers to convince doctors that opioids, like OxyContin, are not as addictive as previously thought, which in turn led to more doctors prescribing them for minor injuries. For perspective, between 1992 and 2002, Oxycontin prescriptions (opioid pills) increased from 620.00 to a staggering 6.2 million, while that number reached 255 million in 2012. During this time, pharmaceutical companies also began to promote the use of opioids for non-cancer-related pain despite the lack of data regarding the long-term effects of opioids. Another aspect of the opioid crisis that has not gone undetected in the last few years is the rise of “synthetic opioids” such as fentanyl. These highly dangerous and addictive drugs have infiltrated many countries, like the United States.

Often called the “third wave” of the opioid epidemic, the fentanyl crisis started in 2013. This wave saw a rise in overdose deaths from non-prescribed synthetic opioids and a decline in prescribed opioid overdoses. The problem with fentanyl and other such medications is their extreme potency (around 100 times more potent than morphine), which puts anyone using them at extreme chance of overdose. The primary sources of Fentanyl and other synthetic opioids are primarily Mexico, using chemicals from China before being pressed into pills that look like Xanax, Adderal, or other well-known pills. The flow of fentanyl, fentanyl-related substances, and fentanyl precursors into the United States is more diversified than ever, with more source countries coming up every single day. Law enforcement operations and policy efforts to disrupt the supply chain has thus proven very difficult.

Since 2014, lawmakers all around the world, and particularly the United States, have been attempting to put a stop in this crisis. Unfortunately, what these elected representatives fail to acknowledge is that the only real way to solve this crisis is not by only securing borders. As we have seen before, investment in infrastructure such as detox centers and mental health facilities is an important part of the equation. International diplomacy, however, is the essential starting point for such actions.

Definition Of Key Terms

Opioids

"Prescription opioids, like OxyContin or Fentanyl, can be prescribed by medics to treat moderate to severe pain but can also have serious risks and side effects,"

Overdose

"A drug overdose is the ingestion of a drug in excessive quantities, to the point when the human body cannot handle the dosage, leading to even fatal repercussions. "

Fentanyl

"A potent synthetic opioid drug approved by the Food and Drug Administration (FDA) for use as an analgesic (pain relief) and aesthetic. It is approximately 100 times more potent than morphine and 50 times more potent than heroin as an analgesic."

Substance use disorders (SUD)

"A substance use disorder (SUD) is a treatable mental disorder that affects a person's brain and behavior, leading to inability of controlling the use of legal or illegal drugs, alcohol, or medications. Addiction is one of the worst symptoms of SUD."

Opioid use disorder (OUD)

"Opioid use disorder (OUD) is characterized by the compulsive use of opioid drugs even when the physical and emotional well-being of an individual is impaired. The use of both legally and illegally prescribed opioids may lead to OUD. From 1999 to 2020, more than 800,000 Americans have died from drug overdoses."

Synthetic opioids

"Synthetic opioids are substances that are synthesized in a laboratory and that act on the same targets in the brain as natural opioids (e.g., morphine and codeine)."

Transnational criminal organizations (TCOs)

"The 2011 Strategy to Combat Transnational Organized Crime defines TCOs as self-perpetuating associations who operate transnationally for the purpose of obtaining power, influence, monetary and/or commercial gains, wholly or in part by illegal means, while protecting their activities through a pattern of corruption and/ or violence, or while protecting their illegal activities through a transnational organizational structure and the exploitation of transnational commerce."

Drug potency

"An expression of the activity of a drug in terms of the concentration or amount of the drug required to produce a defined effect."

Timeline of Events

Date	Description of Event
1961	Single Convention on Narcotic Drugs: international treaty aimed at regulating the production, distribution, and use of narcotic drugs.
1980	"Addiction Rare in Patients Treated with Narcotics" critical research paper published in the New England Journal of Medicine
1986	"Chronic Use of Opioid Analgesics in Non-Malignant Pain: Report of 38 Cases"
2016	Comprehensive Addiction and Recovery (CARA) Act
2018	SUPPORT (Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment for Patients and Communities) Act

Background Information

First wave of the opioid pandemic

The opioid epidemic or crisis is a series of events that has led to the deaths of thousands of people all over the world. The roots of this crisis can be traced back to the 1980s, when many medical journals started publishing studies that supported that opioids are "safe" and not as addictive as previously thought.

In the 2000's, the pharmaceutical industry started aggressively marketing their products to doctors, in search of an opportunity to maximize profits. In turn, opioids were being prescribed for more and more minor injuries. The misinformation around the effects of long-term opioid use led to higher numbers of addicted individuals.

Evidently, one of the most significant contributors to the opioid epidemic was the misconception that prescription opioids were less harmful than illegal drugs. The fact that medical professionals prescribed these medications was enough a reassurance for many patients, who were unaware of the dangers. This slippery slope eventually led to the non-medical use of prescription opioids, as some either sought their euphoric effects or used them to self-medicate for emotional pain and stress.

As the epidemic evolved, government agencies and law enforcement started pushing back on the over-prescribing of opioids. Unfortunately, government policy and regulatory bodies failed to consider providing support to those addicted. As a result, addicted individuals, unable to afford legal medication, turned to the illicit drug market. This transition often led to the use of dangerous substances, like heroin.

Second wave of the opioid epidemic

The second wave of the opioid epidemic is often associated with the rapid increase in heroin overdose deaths. This comes as a direct result of the measures taken to combat the first wave. Efforts made to substantially decrease opioid prescribing, not only rendered their legal acquisition unfeasible, but also alienated addicted individuals. The latter turned to heroin, a much more affordable option.

The drug is widely available and cheap. Made from seeds of certain species of poppy, heroin is an extremely powerful illegal opioid. During the second wave of the epidemic, drug use skyrocketed within all age and socioeconomic groups.



Figure 1: The rise of different opioid types



Figure 2: Overdose deaths of specific opioids

The third wave of the opioid epidemic

The third wave of the opioid epidemic, as characterized by the Centers for Disease Control and Prevention (CDC) of the US government, saw an increase in synthetic opioid overdose deaths. These opioids are lab-made, unlike their naturally occurring counterparts that are collected from seed pods of a certain variety of poppy plants. Although both drug types act on regions of the brain, potency levels differ.

According to the CDC, Fentanyl is up to 50 times stronger than heroin and 100 times stronger than morphine. As a medical response to drug addiction, law enforcement officers and various NGOs have been handing out "Narcan", which is the first ever over-the-counter opioid overdose blocker. On the left, the amount of fentanyl needed for an overdose is provided, in comparison to a United States penny.

Figure 3: Deadly amount of fentanyl, with a US penny for scale

Ongoing challenges in today's opioid epidemic

As of 2023, opioid prescriptions have significantly been lowered, but the issue of overdoses still prevails. Unfortunately, limited access to addiction treatment services remains an obstacle. This is particularly evident in the underfunded areas of the US, where healthcare resources and mental counseling are scarce.

Unfortunately, drug addiction and mental health problems are things that mostly hit underrepresented and marginalized communities. Today, our main concern in the opioid epidemic is not prescription drugs, but illicitly made synthetic opioids like fentanyl. These drugs are alarmingly potent and 2 mg are enough to kill the consumer. Another worrying issue is that many overdoses in the United States today happen by accident; individuals consume substances that have been "laced" with Fentanyl.

Stakeholders

Food and Drug Administration (FDA)

The FDA is the US regulatory agency that gives the green light for new medications and patents. It is regarded as responsible for every food and drug related incident in the United States. It is the agency that did not act when the first wave of the opioid epidemic was right around the corner, by allowing pharmaceutical companies to aggressively market opioids without prior studies or any sort of approval. The epidemic FDA failed to contain in 2010 can still be seen today.

The Pharmaceutical industry

Pharmaceutical companies, like Jonson & Jonson and Purdue Pharma, are considered as the main contributors to the opioid crisis. The spread of misinformation was what initially triggered the domino effect of the three opioid waves.

At Purdue Pharma, executives decided to aggressively market opioids as a low-risk pain relief medication. For instance, in 2006, 215,917,663 opioid prescriptions were given out to patients. Given that this number accounts for 72.4 opioid prescriptions per 100 people, it should not be forgotten that Purdue said its biggest barrier to success was getting enough supply of Oxycodone.

The same is true for Jonson & Jonson. The US-based big pharma behemoth adopted a 15-year-long campaign to promote opioid products as safe analgesic medication, with a low risk of addiction. Since they were the No. 1 supplier of opioid-active ingredients in the United States, Johnson & Johnson had every incentive to boost the opioid market as a whole. This "unbranded" marketing worked. Between 2000 and 2011, Johnson & Johnson sales representatives targeted Oklahoma doctors nearly 150,000 times, ensuring extreme prescriptions of their drugs.

China

Currently, China remains the primary exporter of fentanyl and fentanyl-related substances, which are trafficked through the international mail and express consignment operations environments. Most fentanyl-related substances trafficked into the United States originate from China.

On May 1, 2019, the country officially pledged to regulate all forms of fentanyl as a class of drugs, fulfilling the commitment President Xi Jinping had made during the G-20 Summit. The implementation of the new measure includes investigations of known fentanyl manufacturing areas, stricter control of internet sites advertising related products, stricter enforcement of shipping regulations, and the creation of special teams to investigate organized crime and fentanyl trafficking.



Figure 5: The drug pathways into the United States

Mexico

Mexican TCOs are producing increased quantities of fentanyl, with some using rogue laboratories and processing methods. The DEA, working with Mexican officials, has managed to seize numerous illicit labs in 2018 and 2019.

India

In 2017, the DEA provided information to India's Directorate of Revenue Intelligence, resulting in the takedown of an illicit fentanyl laboratory in Indore. International cartels would initially supply the Indian TCO with fentanyl precursor chemicals. A Chinese associate of the same cartel would then synthesize fentanyl and traffic it from India to Mexico, and then to the United States. After these discoveries and the cooperation with the US, India remains keen to stop the illegal opioid trade.

Portugal

Portugal used to be Europe's worst country for drug overdose. In 1999, use of heroin, cocaine, and other hard drugs was rampant, with approximately 100,000 Portuguese (1% of the population) reporting an addiction to hard drugs. Now, Portugal is a public-health success story with a regulation and recovery system that has been copied by many other European states. The country decided not to legally persecute drug users but provide them with mental assistance and consultation instead. Recovery programs and detoxification also played a big part in Portugal's success. Additionally, every health district in the country has outreach teams that visit addicts every day and get to know their stories and needs.

United States of America

The US is both the main recipient of drug trafficking and the country with the highest death toll due to overdose. The US government have been trying to eradicate drug overdose and stop the path of illicit drugs coming into the country. States like Nevada, New Mexico, and New York were the first to legalize supervised injection centers to limit overdose deaths and speed up addiction recovery.

Drug Enforcement Administration (DEA)

Law enforcement agencies such as the DEA have been trying to crack down on illegal drug rings from the start of this epidemic. Although the American agency has been partially successful, it has not managed to cater for the lives of those addicted on a federal level. International diplomacy and cooperation are needed, in order to protect the rights of addicted individuals and establish international agencies for the regulation of illicit opioid trade and the promotion of rehabilitation programs.

Relevant UN resolutions, treaties, and events (Previous attempts)

Single Convention on Narcotic Drugs

The Single Convention on Narcotic Drugs (1961) is an international treaty that controls the trafficking and production of specific narcotic drugs and lays down a system of regulations, like licenses and requirements for research.

Joint Statement on the opioid crisis

At the time of the Opioid Summit, the Joint Statement of Action included over 30 partners with multiple commitments spanning the key areas of prevention, treatment, and overdose harm reduction in Canada. Since then, a number of new organizations or groups have become partners. Currently, there are 54 Joint Statement of Action partners, including governments and NGOs. The Statement comprises 202 commitments to take individual and collective action to address the opioid crisis. It focuses on the progress achieved by non-governmental partners, including health professional associations and national organizations.

Controlled Substances Act

The Controlled Substances Act (CSA) placed all substances which were in some manner regulated under existing federal law into one of five categories, formally known as "schedules". This placement is based on the substance's medical use, potential for abuse, and safety, or dependence liability. Proceedings to add, delete, or change the schedule of a drug or other substance may be initiated by the Drug Enforcement Administration (DEA), the Department of Health and Human Services (HHS), or by petition from any interested party. This categorization of opioid drugs is important to prevent misinformation regarding prescription safety.

Comprehensive Addiction and Recovery Act (CARA)

CARA is extensive legislation designed to address many components of the opioid epidemic, including prevention, treatment, recovery, law enforcement, criminal justice reform, and overdose reversal. It authorizes more than $181 million each year in new federal funding to overcome the opioid epidemic. It mandates the implementation of programs and services across the United States to address substance use disorders (SUDs) and recovery.

Substance Use-Disorder Prevention that Promotes Opioid Recovery and Treatment (SUPPORT) for Patients and Communities Act

The SUPPORT Act (2018), amended the Controlled Substances Act to expand the conditions a practitioner must meet to provide medication-assisted treatment and expand the options available for a physician to be considered a qualifying physician. The SUPPORT Act removed the time period for a nurse practitioner or physician assistant to be considered a qualifying other practitioner, and revised the definition of a qualifying practitioner. The SUPPORT Act also allows a pharmacy to deliver prescribed controlled substances to a practitioner's registered location for the purpose of maintenance or detoxification treatment.

Possible Solutions

Programs and infrastructure for addicted individuals

In order to fully resolve the opioid crisis, we must understand that stopping the production and trafficking of illegal drugs is not a viable solution. Instead, delegates must focus on creating infrastructure that aims to provide services to addicted individuals, whether that would be access to affordable healthcare and rehabilitation services, or access to mental health professionals.

More specifically, delegates must follow the steps of other UN states such as Portugal and Germany, to create safe and supervised injection sites. These facilities will ensure that proper medical equipment is used while using drugs, and will also serve as a measure to prevent overdoses. Furthermore, delegates should also focus on creating a support network where rehabilitation and mental health are possible. One great example of using rehabilitation treatment as a way to also learn vocational skills and qualifications, that will help addicted individuals self-sustain themselves.

Creation of a legal framework to regulate the medical industry

The pharmaceutical industry and its profiteering tendencies are the main problems when talking about addiction to prescription drugs. Delegates need to regulate this incredibly large industry that brought in 110$ billion in just the United States in 2022. This will not be an easy task. Governmental restrictions need to be applied to all pharmaceutical companies when they are marketing new medication. Such measures could be done through the United Nations Office on Drugs and Crime or other agencies to ensure that a prescription opioid crisis will not happen again.

Further Reading

CDC. "U.S. Opioid Dispensing Rate Maps | Drug Overdose | CDC Injury Center." *Www.cdc.gov*, 23 June 2021, www.cdc.gov/drugoverdose/rxrate-maps/index.html

"The Opioid Crisis and Recent Federal Policy Responses." *Congressional Budget Office*, www.cbo.gov/publication/58532.

"Unclassified Fentanyl Flow to the United States - Dea.Gov." *Drug Enforcement Administration | DEA*, Jan. 2020, www.dea.gov/sites/default/files/2020-03/DEA_GOV_DIR-008-20%20Fentanyl%20Flow%20in%20the%20United%20States_0.pdf aaa

Bibliography

"Fentanyl." *DEA*, www.dea.gov/factsheets/fentanyl .

"Substance Use and Co-Occurring Mental Disorders." *National Institute of Mental Health*, U.S. Department of Health and Human Services, www.nimh.nih.gov/health/topics/substance-use-and-mental-health

"Opioid Use Disorder." Johns Hopkins Medicine, 11 Nov. 2022, www.hopkinsmedicine.org/health/conditions-and-diseases/opioid-use-disorder

"Drug Facts Sheet: Synthetic Opioids - Dea.Gov." *DEA | Drug Enforcement Administration*, 2020, www.dea.gov/sites/default/files/2020-06/Synthetic%20Opioids-2020.pdf

New Face of Transnational Crime Organizations (TCOs) | https://nsiteam.com/the-new-face-of-transnational-crime-organizations-tcos/

Portenoy, Russell K, and Kathleen M Foley. "Chronic Use of Opioid Analgesics in Non-Malignant Pain: Report of 38 Cases." *Pain*, U.S. National Library of Medicine, 25 May 1986, https://pubmed.ncbi.nlm.nih.gov/2873550/

Ciccarone, Daniel. "The Triple Wave Epidemic: Supply and Demand Drivers of the US Opioid Overdose Crisis." *The International Journal on Drug Policy*, U.S. National Library of Medicine, Sept. 2019, www.ncbi.nlm.nih.gov/pmc/articles/PMC6675668/

"The Opioid Crisis and Recent Federal Policy Responses." *Congressional Budget Office*, www.cbo.gov/publication/58532.

"Fentanyl Facts." *Centers for Disease Control and Prevention*, 6 Sept. 2023, www.cdc.gov/stopoverdose/fentanyl/index.html
"Fentanyl." DEA | Drug Enforcement Administration, www.dea.gov/factsheets/fentanyl

CDC. "U.S. Opioid Dispensing Rate Maps | Drug Overdose | CDC Injury Center." *Www.cdc.gov*, 23 June 2021, www.cdc.gov/drugoverdose/rxrate-maps/index.html

After Resting Case, State Points to Critical Evidence That Shows Johnson & Johnson Is Kingpin behind State's Opioid Epidemic | Oklahoma Attorney General." *Oag.ok.gov*, https://oag.ok.gov/articles/after-resting-case-state-points-critical-evidence-shows-johnson-johnson-kingpin-behind

"Fentanyl Flow to the United States DEA Intelligence Report." 2020, https://www.dea.gov/sites/default/files/2020-03/DEA_GOV_DIR-008-20%20Fentanyl%20Flow%20in%20the%20United%20States_0.pdf

"Unclassified Fentanyl Flow to the United States - Dea.Gov." *Drug Enforcement Administration | DEA*, Jan. 2020, www.dea.gov/sites/default/files/2020-03/DEA_GOV_DIR-008-20%20Fentanyl%20Flow%20in%20the%20United%20States_0.pdf

Executive Summary about the Joint Statement of Action a Year in Review. 2016 https://www.ccsa.ca/sites/default/files/2019-04/CCSA-Joint-Statement-of-Action-Opioid-Crisis-Annual-Report-2017-en.pdf

H;, Porter J;Jick. "Addiction Rare in Patients Treated with Narcotics." *The New England Journal of Medicine*, U.S. National Library of Medicine, https://www.nejm.org/doi/full/10.1056/NEJM198001103020221

Forum: *World Health Organization (WHO**)***
Issue: *Facilitating the development of generic drugs in LEDCs*
Student Officers: *Artemis Polychronopoulou Komini (Chair); Ritsos Alexandros Panagiotis (Co-Chair)*

Introduction

In recent years, the global pharmaceutical landscape has witnessed a growing emphasis on improving access to essential medications, particularly in Less Economically Developed Countries (LEDCs). Generic drugs, which offer cost-effective alternatives to their brand-name counterparts, have emerged as a crucial solution in addressing the healthcare disparities in these regions. The development and accessibility of generic drugs have the potential to significantly enhance healthcare outcomes by providing affordable treatments for a wide range of medical conditions. In this study guide, we will explore the problems associated with facilitating the development of generic drugs in LEDCs. By analyzing the challenges, strategies, and implications associated with this endeavor, this guide aims to shed light on the intricate interplay between pharmaceutical innovation, regulatory frameworks, and the urgent need for equitable global healthcare.

The journey toward enabling the production and distribution of generic drugs in LEDCs is marked by intricate legal, economic, and technological considerations. Historically, such countries have encountered obstacles in their efforts to foster a thriving pharmaceutical sector. Issues such as intellectual property rights, regulatory compliance, and limited research and development resources have hindered the local production of affordable medicines. However, with the growing recognition of the ethical imperative to ensure universal access to healthcare, various stakeholders have initiated efforts to reshape the landscape and promote collaboration between governments, industry players, and international organizations. This study guide navigates through these evolving dynamics and seeks to provide insights into the viable pathways for enabling the development of generic drugs that are not only medically efficacious, but also financially viable for LEDCs.

By examining the strategies that have shown promise in overcoming barriers, such as compulsory licensing agreements and technology transfer initiatives, this study aims to contribute to the discourse on fostering pharmaceutical self-reliance in LEDCs. Furthermore, the implications of an improved infrastructure for generic drug production extend beyond healthcare access; they encompass economic growth, scientific advancement, and global health security. As the world grapples with the ongoing challenges posed by both communicable and non-communicable diseases, the development of affordable generic drugs holds the potential to reshape healthcare paradigms in LEDCs and improve public health.

Definition of Key Terms

More Economically Developed Country (MEDC)

"MEDCs are nations that exhibit a high level of economic development, characterized by advanced industrialization, well-developed infrastructure, a strong healthcare and education system, and a relatively high income per capita."

Less Economically Developed Country (LEDC)

"LEDCs are low-income countries confronting severe structural impediments to sustainable development. They are highly vulnerable to economic and environmental shocks and have low levels of human assets."

Generic drug

"A generic drug is a medication created to be the same as an already marketed brand-name drug in dosage form, safety, strength, route of administration, quality, performance characteristics, and intended use."

Healthcare Disparities

"Inequalities in access to healthcare services, often due to socioeconomic factors, which result in varying health outcomes among different populations. "

Compulsory Licensing

"A legal mechanism that allows a government to license the production of a patented product to a third party without the patent holder's consent, typically in cases of public health emergencies or to ensure affordable access to essential medications."

Technology Transfer

"The process of sharing or transferring technological knowledge, expertise, and methods from one entity to another, often involving the transfer of manufacturing processes and know-how to facilitate local production of pharmaceuticals."

Timeline of Events

1970	The World Health Organization (WHO) establishes the Model List of Essential Medicines to show the importance of access to essential drugs.
1994	The Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement is established under the World Trade Organization (WTO), requiring member nations to grant product patents on pharmaceuticals, significantly impacting access to generic drugs.
2001	The Doha Declaration on TRIPS and Public Health is adopted by WTO members, affirming the flexibility of TRIPS to protect public health interests and ensure access to medicines in developing countries.

2001-05	Indian pharmaceutical companies began producing generic versions of patented ARVs, dramatically reducing the cost of HIV/AIDS treatment
2003	The World Health Organization launches the "3 by 5" initiative, aiming to provide antiretroviral therapy to three million people living with HIV/AIDS in developing countries by 2005.
2020-	The COVID-19 pandemic highlights the importance of access to medicines, with many LEDCs not obtaining vaccines and treatments.

Background Information

Understanding the value of generic drugs

The issue of access to affordable and essential medications has long been a concern in Low- and Middle-Income Countries (LEDCs). The pharmaceutical industry has traditionally been dominated by a handful of multinational corporations producing brand-name drugs, resulting in high prices that often place life-saving treatments beyond the reach of many LEDCs. The introduction and development of generic drugs has emerged as a potential solution to address this access gap.

The concept of generic drugs revolves around the production of equivalent versions of brand-name drugs once the original patent protection has expired. This allows other manufacturers to produce the same drug, utilizing the same active ingredients, dosage forms, routes of administration, and quality standards, but at significantly lower costs due to reduced research and development (R&D) expenses. Generic drugs have the potential to offer substantial cost savings while maintaining comparable efficacy and safety profiles to their brand-name counterparts.

The history of generic drugs and patterns in medicine

The historical precedent for the development of generic drugs can be traced back to the 19th century, with the emergence of early pharmaceutical compounding practices. However, it was in the 20th century that the concept gained prominence, driven by a growing recognition of the need for affordable medications.

The Model List of Essential Medicines, introduced in the 1970s by the WHO, highlighted the importance of making essential medications accessible to all, regardless of economic status. This concept laid the foundation for advocating the production and distribution of generic drugs, especially in resource-limited settings.

The causes of the generic drug crisis

The hindrance of access to generic drugs in Less Economically Developed Countries (LEDCs) can be attributed to several interconnected causes.

Stringent intellectual property regulations, often imposed as a result of international trade agreements like the Trade-Related Aspects of Intellectual Property Rights (TRIPS), grant extended patent protection to pharmaceutical companies. This restricts the production and distribution of generic versions of essential medicines.

The lack of resources and infrastructure in many LEDCs hampers their ability to manufacture and regulate generic drugs efficiently. These countries often depend on imported brand-name medications, which are considerably more expensive, limiting access for their populations. The dominance of multinational pharmaceutical companies, who lobby for patent protections and market exclusivity, further exacerbates the issue. Moreover, pharmaceutical companies' reluctance to voluntarily license their patents for generic production, even in the face of public health crises, can hinder access to affordable medications in LEDC markets.

The Trade-Related Aspects of Intellectual Property Rights Agreement

One of the pivotal moments in the history of generic drugs was the establishment of the Agreement on Trade-Related Aspects of Intellectual Property Rights (TRIPS) under the WTO in 1994. TRIPS introduced stringent intellectual property regulations, including extended patent protection periods, which significantly impacted the availability of affordable generic drugs. This agreement presented a challenge to LEDCs, as it extended the monopoly rights of big pharma, delaying the entry of generic versions of essential medications into the market.



Figure 6: Global pharmaceutical industry profits (Statista)

The Doha Declaration

In response to the challenges posed by TRIPS, there were instances of legal mechanisms being employed to facilitate access to generic drugs. Notably, the Doha Declaration on TRIPS and Public Health in 2001 reaffirmed the right of WTO member countries to prioritize public health over patent rights. This declaration recognized the need for flexibility in patent laws to ensure access to affordable medications, particularly in the context of public health emergencies such as HIV/AIDS.

The current crisis

As the 21st century progressed, various LEDCs faced mounting health crises, such as the HIV/AIDS epidemic and COVID-19. The urgency of addressing these crises lead to new calls for facilitating the development and distribution of generic drugs, even within the constraints of existing intellectual property frameworks.

Stakeholders

India

India has played a pivotal role in the global issue of facilitating generic drugs, particularly in Less Economically Developed Countries (LEDCs). With its historic Patents Act of 1970 and subsequent amendments, India created an environment conducive to the development and production of affordable generic medicines. These laws initially allowed only process drug patents, enabling Indian pharmaceutical companies to reverse-engineer and produce generic versions of patented medications. This move not only helped India meet its domestic healthcare needs but also positioned it as the "pharmacy of the developing world."

Indian pharmaceutical companies like Cipla and Ranbaxy have been instrumental in providing low-cost generic drugs for diseases like HIV/AIDS, tuberculosis, and malaria, significantly improving access to essential medicines for millions in LEDCs. India's commitment to affordable healthcare has been crucial, serving as a beacon for other nations in ensuring access to affordable medicines.

Thailand

Thailand is a key player in generic drugs, particularly in the context of public health and access to essential medications. The country has adopted a proactive approach to addressing healthcare disparities by utilizing compulsory licensing provisions to make crucial drugs more affordable and accessible. Thailand's stance on affordable medicine has been especially notable in the case of HIV/AIDS, where it has successfully manufactured generic antiretroviral drugs, significantly reducing treatment costs and expanding access for its population and neighboring countries.

This approach has not only improved the health outcomes of its citizens but has also served as a model for other LEDCs seeking to balance the interests of public health with those of the pharmaceutical industry. Thailand's commitment to the facilitation of generic drugs underscores the vital role that policy and innovation can play in addressing healthcare challenges and advancing global health equity.

Brazil

Brazil has emerged as a significant contributor to the facilitation of generic drugs, particularly in addressing healthcare disparities and enhancing access to essential medications. The country has demonstrated a commitment to leveraging generic pharmaceuticals to reduce the cost of treatment for chronic and life-threatening diseases, notably HIV/AIDS. Brazil's proactive approach to pharmaceutical production and access to medicines, including the use of compulsory licensing, has helped establish a robust generic drug industry. Brazil's leadership in promoting the use of generic drugs underscores the critical role that innovative policy measures can play in enhancing healthcare equity and ensuring that lifesaving treatments are accessible to all, regardless of economic circumstances.

Haiti

Haiti has had a troubled history regarding generic drug shortages. The country's healthcare system has long been underfunded and ill-equipped to meet the healthcare needs of its population. Political instability, natural disasters, and limited resources have further strained the healthcare infrastructure, resulting in inconsistent access to essential medications, including generic drugs. This situation has had dire consequences for the management of prevalent diseases such as HIV/AIDS, tuberculosis, and cholera. The devastating 2010 earthquake exacerbated these challenges, disrupting supply chains and healthcare services. Although international aid and initiatives have aimed to improve healthcare access and availability of generic drugs in Haiti, significant obstacles persist. The nation's historic highlights the urgent need for sustained efforts to strengthen healthcare infrastructure and ensure reliable access to affordable medications for its vulnerable population.

South Africa

South Africa has played a pioneering role in facilitating the availability of generic drugs in the African continent, making significant strides in improving healthcare accessibility. The country has been at the forefront of addressing the challenges posed by high drug prices, particularly in the context of the HIV/AIDS epidemic. South Africa's determined efforts in negotiating with pharmaceutical companies to lower medication costs and its successful legal battles to increase access to generic antiretroviral drugs have set important precedents for the entire continent. South Africa's steadfast commitment to promoting the use of generic drugs has had a transformative impact on health equity in the African continent.

Sierra Leone

In Sierra Leone, the situation regarding generic drugs presents a complex healthcare challenge. The country's healthcare system faces significant limitations, including limited resources, inadequate healthcare infrastructure, and weak pharmaceutical regulations, which have resulted in periodic shortages of essential medication, such as in the 2014-2016 Ebola outbreak. To address these challenges and ensure more reliable access to affordable medicines, there has been a growing recognition of the importance of transitioning to a predominantly generic drug-based healthcare model. By mandating that all prescription and dispensing of medicines in the public sector be done using generic drugs, Sierra Leone could potentially lower healthcare costs and increase the availability of essential medications.

United States of America

The United States has played a pivotal role in both the historical evolution and the current landscape of generic drugs. The introduction of generic drugs in the USA can be traced back to the Drug Price Competition and Patent Term Restoration Act of 1984, commonly known as the Hatch-Waxman Act.

This legislation revolutionized the generic pharmaceutical industry, by establishing a framework for generic drug approval and market entry. Generic manufacturers could file Abbreviated New Drug Applications (ANDAs) to demonstrate that their products were equivalent to brand-name drugs, expediting the approval process. Furthermore, the Drug Price Competition and Patent Term Restoration Act allowed generic companies to challenge the patents held by brand-name manufacturers, paving the way for earlier market entry and increased competition.

World Trade Organization (WTO)

The World Trade Organization (WTO) is the only global international organization dealing with the rules of trade between nations. WTO's goal is to help producers of goods and services, exporters, and importers conduct their business.

Food and Drug Administration (FDA)

The Food and Drug Administration has a rich history when it comes to regulating generic drugs. The agency's involvement in this domain began with the passage of the Drug Amendments of 1962, which required manufacturers to prove the efficacy, safety, and quality of their drugs through rigorous scientific testing before gaining FDA approval. However, it wasn't until the Drug Price Competition and Patent Term Restoration Act of 1984, that the FDA's role in the regulation of generic drugs significantly expanded. This landmark legislation streamlined the approval process for generic drugs by allowing manufacturers to file Abbreviated New Drug Applications (ANDAs), that demonstrated the equivalence of their products to brand-name drugs. Additionally, it provided a mechanism for generic companies to challenge the patents held by brand-name manufacturers, enabling earlier market entry and greater competition. Over the years, the FDA has continued to refine its regulatory processes for generic drugs, ensuring that these alternatives are held to the same rigorous standards of safety, efficacy, and quality as their brand-name counterparts. However, corruption allegations in favor of the pharmaceutical industry are often reported

Relevant U.N. Resolutions, Treaties and Events

WHO Model List of Essential Medicines, 2023

It is "intended as a guide for countries or regional authorities to adopt or adapt in accordance with local priorities and treatment guidelines for the development and updating of national essential medicines lists."

Drug Price Competition and Patent Term Restoration Act (Hatch-Waxman)

The Drug Price Competition and Patent Term Restoration Act is a comprehensive legal framework enacted in 1984 to streamline the process for generic pharmaceutical approvals and preserve incentives for innovation, including the creation of a procedure for patient litigation involving generic pharmaceuticals.

One of the key provisions of this act was that it allowed generic manufacturers to file Abbreviated New Drug Applications (ANDAs), a streamlined pathway that required them to demonstrate the equivalence of their generic product to a brand-name drug in terms of active ingredients, strength, dosage form, route of administration, and labelling. Furthermore, the Drug Price Competition and Patent Term Restoration Act introduced a mechanism known as "paragraph IV certification," which allowed generic companies to challenge the patents held by brand-name manufacturers. In doing so, generic manufacturers could potentially enter the market before the expiration of the patent, triggering price competition and making affordable generic alternatives available to consumers sooner.

The “3 by 5” initiative, 2003

The United Nations' "3 by 5" initiative, officially known as the "3 by 5" Initiative on AIDS, was launched by the World Health Organization (WHO) in 2003 with the ambitious goal of providing antiretroviral therapy (ART) to three million people living with HIV/AIDS in developing countries by the end of 2005. This initiative was a response to the growing global HIV/AIDS pandemic, particularly in LEDCs, where access to life-saving treatment was limited due to high costs. "3 by 5" aimed to scale up HIV/AIDS treatment and care services, increase the availability of affordable generic antiretroviral drugs, strengthen healthcare systems in affected countries, and improve overall access to healthcare. Although the initiative did not achieve its target by the set deadline, it made significant progress in paving the way for subsequent efforts to combat the epidemic and emphasizing the importance of global cooperation in addressing public health crises in LEDCs.

Trade-Related Aspects of Intellectual Property Rights (TRIPS), 1994

The Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, established in 1994 under the World Trade Organization mandated that member nations provide product patents on pharmaceuticals, which extended patent protection to medicines. While this was intended to protect the interests of pharmaceutical companies and promote innovation, it posed challenges for LEDCs in accessing affordable medicines. However, TRIPS also included flexibilities that allowed countries to issue compulsory licenses and engage in parallel importation of patented drugs, under certain conditions. These flexibilities enabled some LEDCs, like India, to develop and manufacture generic versions of essential medications, such as antiretroviral drugs for HIV/AIDS, at a fraction of the cost of brand-name counterparts, expanding access to vital treatments for their populations.

Doha Agreement, 2001

The Doha Agreement, officially known as the Doha Declaration on the TRIPS Agreement and Public Health, was adopted at the Fourth Ministerial Conference of the World Trade Organization (WTO) in Doha, Qatar, in November 2001.

This landmark declaration reaffirmed the primacy of public health over intellectual property rights by recognizing the flexibility of the Trade-Related Aspects of Intellectual Property Rights (TRIPS) agreement, particularly regarding pharmaceutical patents. The Doha Agreement emphasized that TRIPS should not prevent WTO member countries, especially those in Less Economically Developed Countries (LEDCs), from taking measures to protect public health and ensure access to affordable medicines. It explicitly recognized the right of countries to issue compulsory licenses for essential medications and engage in parallel importation, allowing them to produce or import generic versions of patented drugs during health emergencies or to address public health crises like HIV/AIDS.

The Doha Agreement marked a significant shift in global trade policy, acknowledging the importance of striking a balance between intellectual property rights and the urgent need for accessible and affordable medicines in LEDCs.

Possible Solutions

Compulsory Licensing and Flexibilities within Intellectual Property Laws

A comprehensive solution to the issues surrounding generic drugs in LEDCs would involve the use of compulsory licensing. First, international organizations and MEDCs should increase funding and support for LEDCs to strengthen their healthcare infrastructure, ensuring efficient procurement, distribution, and monitoring of generic drugs. Simultaneously, diplomatic efforts should be made to negotiate with pharmaceutical companies to lower the prices of essential medications through voluntary licensing agreements. However, if negotiations fail, compulsory licensing should be utilized judiciously to allow local manufacturers to produce affordable generics, emphasizing public health interests. Regulations should be strengthened to ensure the quality and safety of generic drugs, fostering public trust. Public awareness campaigns should educate communities about the efficacy and safety of generics. Additionally, trade policies should prioritize public health, granting LEDCs flexibility to use compulsory licensing without trade sanctions. This comprehensive approach, combining international cooperation, local capacity building, policy reforms, and strategic use of compulsory licensing, can bridge the gap in generic drug access in LEDCs, improving healthcare and reducing disease burdens.

Technology Transfer and Capacity Building

MEDCs and international organizations could potentially facilitate the transfer of manufacturing processes, technical know-how, and quality control practices to manufacturers in LEDCs. This knowledge exchange would equip local manufacturers with the expertise needed to produce high-quality generic drugs that meet international standards. Collaborative initiatives between pharmaceutical companies and local entities could eventually lead to joint ventures, where technology transfer is coupled with skills development. This approach not only fosters domestic pharmaceutical self-reliance but also stimulates economic growth by creating employment opportunities and driving innovation within the pharmaceutical sector.

Further Reading

"What Is Technology Transfer? (Definition and Examples)." *TWI*, www.twi-global.com/technical-knowledge/faqs/what-is-technology-transfer

"World Trade Organization | The Doha Declaration Explained." *WTO*, www.wto.org/english/tratop_e/dda_e/dohaexplained_e.htm#top

"Who Model List of Essential Medicines - 23rd List." *World Health Organization*, 2023, www.who.int/publications/i/item/WHO-MHP-HPS-EML-2023.02

"World Health Organization and UNAIDS UNVEIL Plan to Get 3 Million AIDS Patients on Treatment by 2005." *World Health Organization*, www.who.int/news/item/01-12-2003-world-health-organization-and-unaids-unveil-plan-to-get-3-million-aids-patients-on-treatment-by-2005

"Generic Medicines: Interchangeability of Who-Prequalified Generics." *World Health Organization*, 1 Jan. 1970, https://apps.who.int/iris/handle/10665/331014

Motari, Marion, et al. "The Role of Intellectual Property Rights on Access to Medicines in the Who African Region: 25 Years after the TRIPS Agreement - BMC Public Health." *BioMed Central*, 11 Mar. 2021, https://rdcu.be/dmfuK

James, Peter Bai, et al. "Exploring the Knowledge and Perception of Generic Medicines among Final Year Undergraduate Medical, Pharmacy, and Nursing Students in Sierra Leone: A Comparative Cross-Sectional Approach." *MDPI*, Multidisciplinary Digital Publishing Institute, 4 Jan. 2018, www.mdpi.com/2226-4787/6/1/3#B4-pharmacy-06-00003

"2014-2016 Ebola Outbreak in West Africa." *Centers for Disease Control and Prevention*, 8 Mar. 2019, www.cdc.gov/vhf/ebola/history/2014-2016-outbreak/index.html

"What Is Hatch-Waxman?" *PhRMA Org*, 12 July 2018, https://phrma.org/en/resource-center/Topics/Cost-and-Value/What-is-Hatch-Waxman

Chahal, Harinder Singh, et al. "Availability, Prices and Affordability of Essential Medicines in Haiti." *Journal of Global Health*, U.S. National Library of Medicine, Dec. 2013, www.ncbi.nlm.nih.gov/pmc/articles/PMC3868824/

Stevens, Hilde, and Isabelle Huys. "Innovative Approaches to Increase Access to Medicines in Developing Countries." *Frontiers in Medicine*, U.S. National Library of Medicine, 7 Dec. 2017, www.ncbi.nlm.nih.gov/pmc/articles/PMC5725781/

Bibliography

"World Trade Organization - Global Trade." *World Trade Organization - Home Page - Global Trade*, www.wto.org/index.htm

Center for Drug Evaluation and Research. "Generic Drugs: Questions & Answers." *U.S. Food and Drug Administration*, FDA, www.fda.gov/drugs/frequently-asked-questions-popular-topics/generic-drugs-questions-answers

"Facilitating Generic Drug Manufacturing: Bolar Exemptions Worldwide." *WIPO*, www.wipo.int/wipo_magazine/en/2014/03/article_0004.html

Stevens, Hilde, and Isabelle Huys. "Innovative Approaches to Increase Access to Medicines in Developing Countries." *Frontiers in Medicine*, U.S. National Library of Medicine, 7 Dec. 2017, www.ncbi.nlm.nih.gov/pmc/articles/PMC5725781/

"Ministry of Health and Sanitation – (Mohs) Sierra Leone." *Ministry of Health and Sanitation*, https://mohs.gov.sl/

Acosta, Angela, et al. "Frontiers | Medicine Shortages: Gaps Between Countries and Global Perspectives." *Frontiers*, 2019, www.frontiersin.org/articles/10.3389/fphar.2019.00763/full

Shukar, Sundus, et al. "Drug Shortage: Causes, Impact, and Mitigation Strategies." *Frontiers in Pharmacology*, U.S. National Library of Medicine, 9 July 2021, www.ncbi.nlm.nih.gov/pmc/articles/PMC8299364/

Motari, Marion, et al. "The Role of Intellectual Property Rights on Access to Medicines in the Who African Region: 25 Years after the TRIPS Agreement - BMC Public Health." *BioMed Central*, 11 Mar. 2021, https://bmcpublichealth.biomedcentral.com/articles/10.1186/s12889-021-10374-y

"Generic Medicines: Interchangeability of Who-Prequalified Generics." *World Health Organization*, 1 Jan. 1970, https://iris.who.int/bitstream/handle/10665/331014/DI303-370-375-eng.pdf?isAllowed=y&sequence=1#:~:text=Approval%20of%20a%20generic%20medicine,the%20innovator%20through%20bioequivalence%20studies.

WHO